CSL is a century-old company and a darling among healthcare stocks, having delivered a 15% annual return over the past 10 years. Currently, investors are spooked by three risks that are getting lots of attention.
Risk 1: Weight-loss drugs
Ozempic improves glycaemic control and can be used 'off label' to assist weight loss. While the drug has been around for years, it's making headlines because researchers are finding new applications for it and easier ways to administer it.
The risk that Ozempic-like drugs, known as GLP-1 agonists, pose to CSL can be split into broad and narrow effects.
On the broad side, Ozempic helps people lose weight by reducing appetite. Ozempic
